Abstract 187P
Background
The tumour microenvironment (TME) in high-grade serous ovarian cancer (HGSOC) is a complex ecosystem that facilitates ovarian cancer progression. However, further investigation is required to elucidate the precise role of the TME.
Methods
In this study, single-cell RNA sequencing was employed to profile the TME in freshly collected HGSOC samples, comprising two normal ovarian cortex samples and six HGSOC samples.
Results
A total of 55,430 single cells obtained from ovarian and HGSOC tissues were subjected to single-cell RNA sequencing (scRNA-seq). The cells were divided into seven clusters, comprising B cells, T and NK cells, myeloid cells, endothelial cells, fibroblasts, epithelial cells and mast cells. The proportion of B cells, myeloid cells, mast cells and T & NK cells was greater in HGSOC samples than in ovary cortex samples, whereas the percentage of epithelial cells was lower in the former. The analysis of intercommunication of epithelial cells with other cell clusters indicated that the interactions between epithelial cells and fibroblast cells, T & NK cells, B cells as well as myeloid cells were enhanced in in HGSOC samples comparing ovary cortex samples. Additionally, we identified a subcluster of epithelial cells (E7) and a subcluster of fibroblast cells (F7) that were implicated in tumour formation. Finally, we examined the intercommunication between E7 and F7. One of the most significant ligand-receptor signals identified was THBS2-CD74.
Conclusions
The results clearly demonstrated an increase in immune cell percentage in ovarian cancer tissue. Malignant cell clusters, designated as fibroblast cells F7 and epithelial cells E7, were also identified. Among the interactions between F7 and E7, the THBS2-CD74 signal emerged as a crucial factor in the tumourigenesis of HGSOC.
Legal entity responsible for the study
Beijing Obstetrics and Gynecology, Capital Medical University.
Funding
National Natural Science Foundation of China (No. 82373397), the Capital’s Funds for Health Improvement and Research (No. 2022-2-2116), Beijing Municipal Administration of Hospitals Incubating Program (No.PX2022057) and Beijing Obstetrics and Gynecology Hospital, Capital Medical University (No. FCYY201915).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
124P - AI-designed cancer vaccines: Antigens from the dark genome are promising cancer vaccine targets
Presenter: Daniela Kleine-Kohlbrecher
Session: Poster Display session
Resources:
Abstract
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
Resources:
Abstract
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
Resources:
Abstract
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
Resources:
Abstract
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
Resources:
Abstract
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
Resources:
Abstract
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
Resources:
Abstract
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
Resources:
Abstract
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session
Resources:
Abstract
133P - The efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor treated advanced non-small cell lung cancer: A single-arm, open-label, multicenter phase II clinical trial
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract